Scholarlink

<p>Readily available and rapid turn-around, bedside assays to measure the effect of the direct oral anticoagulants (DOACs) are not available. This study evaluates a point-of-care (PoC) coagulometer to assess the anticoagulant effects of the DOACs and low molecular weight heparin. Studies were done in fresh spiked blood from healthy volunteers. PoC coagulometer baseline clotting times were half that of the manual whole blood clotting time (WBCT, legacy method) and exhibited a sensitivity to DOAC anticoagulation approximately twice that of WBCT. All %CV values for both methods were &lt; 10% with most being &lt; 5% indicating acceptable precision of both methods. R<sup>2</sup> values for both clotting time and percent rise from baseline were &gt; 0.98 indicating a strong correlation between the two methods. Replicate measurements for all subjects showed a maximum upper %CV value of 5.56% and a maximum upper value of all absolute %Differences of 5.5%, with both criteria meeting predefined acceptance criteria. The dose–response curves for all subjects were linear across the concentration ranges tested. The Perosphere Technology PoC coagulometer detects a range of therapeutic levels of the DOACs apixaban, rivaroxaban, edoxaban, and dabigatran, as well as the low molecular weight heparin, enoxaparin, with high precision and sensitivity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Validation of a whole blood coagulometer sensitive to the direct oral anticoagulants

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月1日

查看全文
  • Sasha H. Bakhru,
  • Xuan Jiang,
  • Lirong Chen,
  • Dardan Osmani,
  • Kelly Kronen,
  • Daryl Mootoo,
  • Stefan Zappe,
  • Jack Ansell

摘要

Readily available and rapid turn-around, bedside assays to measure the effect of the direct oral anticoagulants (DOACs) are not available. This study evaluates a point-of-care (PoC) coagulometer to assess the anticoagulant effects of the DOACs and low molecular weight heparin. Studies were done in fresh spiked blood from healthy volunteers. PoC coagulometer baseline clotting times were half that of the manual whole blood clotting time (WBCT, legacy method) and exhibited a sensitivity to DOAC anticoagulation approximately twice that of WBCT. All %CV values for both methods were < 10% with most being < 5% indicating acceptable precision of both methods. R2 values for both clotting time and percent rise from baseline were > 0.98 indicating a strong correlation between the two methods. Replicate measurements for all subjects showed a maximum upper %CV value of 5.56% and a maximum upper value of all absolute %Differences of 5.5%, with both criteria meeting predefined acceptance criteria. The dose–response curves for all subjects were linear across the concentration ranges tested. The Perosphere Technology PoC coagulometer detects a range of therapeutic levels of the DOACs apixaban, rivaroxaban, edoxaban, and dabigatran, as well as the low molecular weight heparin, enoxaparin, with high precision and sensitivity.